Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $512.98
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 31, 26 |
| Oppenheimer |
| maintain |
| Outperform |
| Outperform |
| Jul 30, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Jul 9, 26 | B of A Securities | maintain | Neutral | Neutral |
| Apr 27, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Feb 27, 26 | RBC Capital | downgrade | Outperform | Sector Perform |
| Feb 27, 26 | Oppenheimer | maintain | Outperform | Outperform |
| Jan 22, 26 | Jefferies | downgrade | Buy | Hold |
| Nov 10, 25 | RBC Capital | maintain | Outperform | Outperform |
| Sep 10, 25 | B of A Securities | maintain | Buy | Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | CHE | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 25.8x | 28.7x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 20.1x | EPS est. 25.49 | Discount |
| Price / Book | 8.3x | 8.8x | In line |
| Price / Sales | 2.6x | 3.4x | Discount |
| EV / EBITDA | 16.2x | 18.7x | In line |
| Return on equity | 29.5% | — | Top tier |
| Gross margin | 30.4% | 34.4% | In line |
| Debt / Equity | 0.40 | 0.25 | Conservative |
| Piotroski / Altman Z | 7/9 | Z 10.48 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 51.91 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 74.67 | Oscillator | Neutral |
| Williams %R (14) | -32.96 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.80 (Hist 1.66) | Oscillator | Strong Buy |
| Average Directional Index (14) | 14.30 (+DI 23.0 / -DI 12.7) | Trend | Neutral |
| EMA 20 | 510.41 | MA | Buy |
| SMA 20 | 508.69 | MA | Buy |
| EMA 50 | 509.40 | MA | Buy |
| SMA 50 | 515.25 | MA | Sell |
| SMA 200 | 460.80 | MA | Strong Buy |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 22, 2026 | 2026-10-22 13:34:10 | View |
| 4 | Oct 22, 2026 | 2026-10-22 13:29:44 | View |
| 4 | Oct 22, 2026 | 2026-10-22 13:25:42 | View |
| 4 | Oct 22, 2026 | 2026-10-22 13:21:22 | View |
| 4 | Oct 22, 2026 | 2026-10-22 13:16:38 | View |
| 4 | Oct 22, 2026 | 2026-10-22 11:24:23 | View |
| 4 | Oct 1, 2026 | 2026-10-01 13:06:53 | View |
| 4 | Sep 30, 2026 | 2026-09-30 14:07:09 | View |
| 4 | Sep 29, 2026 | 2026-09-29 10:51:09 | View |
| 4 | Sep 21, 2026 | 2026-09-21 12:24:09 | View |
Proxy statement (DEF 14A) disclosures
FY2025 · 10-K disclosure
Stock news · updated daily
Chemed (NYSE: CHE - Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to announce earnings of $6.39 per share and revenue of $685.04 million for the quarter. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Investors may visit
Chemed Corporation (NYSE: CHE - Get Free Report) has received an average rating of "Hold" from the seven research firms that are presently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among
CINCINNATI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2026, on Tuesday, October 27, 2026, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m.
Corient Private Wealth LP raised its stake in shares of Chemed Corporation (NYSE: CHE) by 43.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,882 shares of the company's stock after purchasing an additional 1,488 shares during the
Chemed (NYSE: CHE - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Volatility and Risk Chemed has a beta of 0.51, suggesting
Waverly Advisors LLC acquired a new stake in Chemed Corporation (NYSE: CHE) in the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 1,173 shares of the company's stock, valued at approximately $546,000. A number of other institutional investors have also recently modified their holdings of CHE. Eukles
CINCINNATI, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE: CHE) announced it has acquired the largest independent Roto-Rooter franchise, serving a population of approximately 11 million people, for $60.6 million.
Chemed Corporation (CHE) Presents at 2026 Jefferies Healthcare Services and Technology Conference Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 28, 2026 | 5.60 | 6.06 | Beat 8.2% | $673.3M |
| Apr 23, 2026 | 5.30 | 5.65 | Beat 6.6% | $657.5M |
| Feb 25, 2026 | 7.02 | 6.42 | Miss -8.5% | $639.3M |
| Oct 28, 2025 | 5.39 | 5.27 | Miss -2.2% | $624.9M |
| Jul 29, 2025 | 4.78 | 4.27 | Miss -10.7% | $618.8M |
| Apr 23, 2025 | 5.55 | 5.63 | Beat 1.4% | $646.9M |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 20, 26 | Wherley Joel L | officer: CEO - Vitas Healthcare | A-Award | 12,686 @ $512.64 | $6.50M |
| Oct 20, 26 | Lee Spencer S | officer: executive vice president | A-Award | 7,125 @ $512.64 | $3.65M |
| Oct 20, 26 | Judkins Brian C | officer: VP and Chief Legal Officer | A-Award | 9,392 @ $512.64 | $4.81M |
| Oct 20, 26 | Hutton Thomas C | director, officer: vice president | A-Award | 3,964 @ $512.64 | $2.03M |
| Oct 20, 26 | Witzeman Michael D | officer: VP & Chief Financial Officer | A-Award | 12,686 @ $512.64 | $6.50M |
| Oct 20, 26 | Mcnamara Kevin J | director, officer: president and CEO | A-Award | 36,693 @ $512.64 | $18.81M |
| Sep 30, 26 | Lee Spencer S | officer: executive vice president | M-Exempt | 12,099 @ $445.35 | $5.39M |
| Sep 30, 26 | Lee Spencer S | officer: executive vice president | M-Exempt | 12,099 @ $445.35 | $5.39M |